ASX Share rice
Tue 22 Sep 2020 - 09:59:pm (Sydney)

TLX Share Price

TELIX PHARMACEUTICALS LIMITEDTLXPharmaceuticals, Biotechnology & Life Sciences

TLX Company Information

Name:

Telix Pharmaceuticals Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

55 Flemington Road North Melbourne VIC Australia 3051

Phone:

61 4 4914 8448

Co-Founder, MD, CEO & Director:

Dr. Christian P. Behrenbruch B.E., M.B.A., Ph.D., BEng(Hons), MBA, DPhil(Oxon)

Chief Financial Officer:

Mr. Douglas Cubbin FCPA, GAICD

Group Chief Operating Officer:

Mr. Gabriel Liberatore B.Sc., M.A.I.C.D., M.B.A., Ph.D.

Chief Bus. Officer & Head of Investor Relations:

Dr. David N. Cade

VP Sales and Marketing, EMEA:

Mr. Christian Davis

Company Overview:

Telix Pharmaceuticals Limited, an oncology company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia. Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a development collaboration agreement with ARTMS Products Inc. for the manufacture of its prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11 injection) for the imaging of prostate cancer with Positron Emission Tomography (PET). Telix Pharmaceuticals Limited has strategic collaboration with RefleXion Medical for the treatment of high-risk cancers. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.

TLX Share Price Information

Shares Issued:

253.94M

Market Capitalisation:

$444.40M

Revenue (TTM):

$3.28M

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.089

Operating Margin (TTM):

$-13.49

Return On Assets (TTM):

$-0.35

Return On Equity (TTM):

$-0.74

Quarterly Revenue Growth (YOY):

-0.116

Gross Profit(TTM):

$0.94M

Diluted Earnings Per Share (TTM):

$-0.143

TLX CashFlow Statement

CashFlow Date:

2019-12-31

Investments:

$-468,000

Change To Liabilities:

$2.98M

Total Cashflow From Investing Activities:

$-468,000

Net Borrowings:

$-1,167,000

Net Income:

$-27,867,000

Total Cash From Operating Activities:

$-23,333,000

Depreciation:

$4.24M

Change To Inventory:

$101K

Change To Account Receivables:

$-3,635,000

Sale Purchase Of Stock:

$45.25M

Capital Expenditures:

$468K

TLX Income Statement

Income Date:

2019-12-31

Income Before Tax:

$-31,122,000

Net Income:

$-27,867,000

Gross Profit:

$0.94M

Operating Income:

$-28,714,000

Interest Expense:

$355K

Income Tax Expense:

$-3,255,000

Total Revenue:

$3.49M

Total Operating Expenses:

$41.20M

Cost Of Revenue:

$2.54M

TLX Balance Sheet

Balance Sheet Date:

2019-12-31

Intangible Assets:

$37.72M

Total Liabilities:

$32.53M

Total Stockholder Equity:

$70.08M

Other Current Liabilities:

$1.80M

Total Assets:

$102.61M

Common Stock:

$115.94M

Other Current Assets:

$0.94M

Retained Earnings:

$-45,800,000

Other Liabilities:

$20.26M

Good Will:

$4.22M

Other Assets:

$82K

Cash:

$44.60M

Total Current Liabilities:

$10.63M

Short-Term Debt:

$469K

Property - Plant & Equipment:

$1.90M

Net Tangible Assets:

$28.13M

Total Current Assets:

$58.68M

Long-Term Debt:

$292K

Net Receivables:

$745K

Short-Term Investments:

$43.93M

Inventory:

$542K

Accounts Payable:

$6.96M

Non Currrent Assets (Other):

$43.93M

Short-Term Investments:

$43.93

Non Current Liabilities (Other):

$17.09M

Non Current Liabilities Total:

$21.90M

TLX Share Price History

TLX News

03 Sep, 2020
MELBOURNE, Australia and PALO ALTO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announced it has entered into a strategic collaboration agreement with Palo Alto-based Varian Medical Systems, to evaluate the use of advanced prostate cancer imaging within Varian’s radiation treatment planning platform. Under the terms of the agreement, the parties will leverage Telix’s extensive clinical data for imaging prostate-specific membrane antigen (PSMA) with positron emission tomography (PET) to potentially develop new image-guided treatment planning functions, automated analysis and artificial intelligence capabilities within Varian’s radiation treatment planning technology platforms. The goal of the collaboration is to ensure that the latest standard of care in prostate imaging is able to be an integral part of radiation treatment planning.Telix CEO Dr Christian Behrenbruch said “Advanced prostate imaging techniques using PET/CT have evolved as a new standard of care for imaging patients across the prostate cancer continuum, from early through to the advanced stages of disease.1 Given that radiation therapy is a mainstay of treatment for patients with prostate cancer, we believe it is vitally important that we work with Varian, the radiation oncology market leader, to ensure all men with prostate cancer are offered radiation therapy for maximum clinical benefit.”Dr Corey Zankowski, Senior Vice President of Varian’s Oncology Software Solutions said “The additional diagnostic and cancer staging information provided by PSMA PET/CT imaging may offer important insights that impact clinical care decisions for prostate cancer patients. This collaboration with Telix will investigate the potential to incorporate this rich diagnostic information into Varian’s bioinformatics and radiation treatment planning platforms to generate highly personalized and targeted radiation therapy for men with prostate cancer.”About Prostate CancerProstate cancer is the most common cancer in men, with an estimated 192,000 new cases and 33,000 deaths from prostate cancer in the United States expected in 2020.2 Prostate cancer is more common in older men, with approximately 60% of cases diagnosed in men over 65 years of age. Due to high rates of screening, over 90% of prostate cancers are diagnosed early, when the disease is localised to the prostate or nearby tissues. Both surgery and radiation therapy are effective treatment options for men with localised prostate cancer, offering 5-year survival rates over 95%. More than 60,000 men in the United States undergo radiation therapy for prostate cancer annually,3 with advances in medical imaging and radiation treatment planning continuing to increase the effectiveness and reduce the side effects of radiation therapy.4_____________ 1 Trabulsi EJ, et al. Optimum Imaging Strategies for Advanced Prostate Cancer; ASCO Guideline. J Clin Oncol 38: 1963 – 1996 (published online January 15, 2020). 2 American Cancer Society: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html. 3 Prostate Cancer Foundation: https://www.pcf.org/c/treatment-for-prostate-cancer-external-beam-radiation-therapy/. 4 Garibaldi c, et al. Recent advances in radiation oncology. Ecancermedicalscience. 2017; 11: 85.About Telix Pharmaceuticals Limited Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.About Varian Medical Systems Inc.At Varian, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 10,000 employees across 70 countries keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.Telix Corporate Contact Dr Christian Behrenbruch Telix Pharmaceuticals Limited CEO Email: chris@telixpharma.comTelix Investor Relations Dr David N. Cade Telix Pharmaceuticals Limited CBO and Head of Investor Relations Email: david.cade@telixpharma.com
18 Aug, 2020
TOKYO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that the first patient has been dosed in a Phase I/II study of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab) in Japan. The objective of the study, termed the “ZIRDAC-JP” (Zirconium Dosing and Comparison in Japan) study is to confirm the safety and tolerability, as well as sensitivity and specificity of positron emission tomography (PET) imaging with TLX250-CDx to detect clear cell renal cell cancer (ccRCC) in Japanese patients. The patient population for the ZIRDAC-JP trial has been selected to be identical to the global Phase III ZIRCON trial, with comparison to surgical resection (histology) as standard of truth. The study has been carefully designed in consultation with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to collect the necessary data to potentially bridge to the ZIRCON study by confirming that dosing and pharmacology in Japanese patients is consistent with the rest-of-world experience.Telix Pharmaceuticals Japan K.K. President, Dr. Shintaro Nishimura stated, “The ZIRDAC-JP study is the first commercially sponsored clinical trial in Japan in which a zirconium-based diagnostic agent has been studied. Dosing the first patient in the ZIRDAC-JP study represents a significant first step for the Japanese nuclear medicine community to deliver benefit to Japanese cancer patients and to pave the way for the future use of theranostics in Japan. We’d like to express our appreciation to Dr Nakaigawa, the study’s principal investigator at Yokohama City University Hospital, the investigators and the study team for their excellent collaboration, and most importantly the patients who will participate in this trial.”Mr. Masahiro Tanaka, Director of the Medical Division of JFE Engineering Corporation stated, “We are very pleased to have contributed to the successful initiation of the ZIRDAC-JP study with the investigational drug manufactured by JFE Engineering at our Yokohama cyclotron facility. Our centralized manufacturing capabilities will provide the patients and medical community with flexible and convenient access to this novel radiopharmaceutical and will provide the pharmaceutical industry with a significant commercial opportunity.”About the ZIRDAC-JP Study ZIRDAC-JP (Zirconium Dosing and Comparison in Japan, NCT04496089) is a Japanese multi-centre Phase I/II study that will recruit approximately 40 patients in total. The objectives of the study are to determine the safety, tolerability, radiation dosimetry and pharmacokinetics / pharmacodynamics (Phase I), and the sensitivity and specificity of TLX250-CDx PET imaging to detect clear cell renal cell cancer (ccRCC) compared to histologic ‘ground truth’ determined from surgical resection specimens (Phase II).About Telix Pharmaceuticals Limited Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.About JFE Engineering CorporationJFE Engineering is continuing to accelerate the globalization of its engineering business and supply leading-edge technologies to countries around the world. JFE Engineering is committed to creating the foundation for life and a better standard of living through innovation in energy, construction and healthcare. For more information, please visit www.jfe-eng.co.jp.           Telix Japan Contact                                                 Dr. Shintaro Nishimura                                               President & Chief Operating Officer                          Telix Pharmaceuticals Japan K.K.                                                     E: shintaro.nishimura@telixpharma.com                   W: www.telixpharma.com
08 Jul, 2020
RefleXion Medical and Telix Pharmaceuticals announced a strategic collaboration to improve treatment for high-risk or recurrent cancers.
01 May, 2020
MELBOURNE, Australia and LIÈGE, Belgium, May 01, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has submitted a marketing authorisation application (MAA) in Europe for TLX591-CDx (68Ga-PSMA-11 Injection) for the imaging of prostate cancer with Positron Emission Tomography (PET). The submission has been made to the Danish Medicines Agency (DKMA) in its capacity as a reference Competent Authority of a European member state. The DKMA will coordinate and lead the evaluation of Telix’s MAA for TLX591-CDx on behalf of Denmark as well as a selection of European countries, nominated by Telix.
29 Oct, 2019
Telix Pharmaceuticals Limited (ASX:TLX) has today announced that Telix and AusHealth have entered into a collaboration and technology licensing agreement for a novel Molecularly Targeted Radiation (MTR) platform called APOMAB®1 intended for the treatment of ovarian and lung cancers. The research behind the APOMAB technology was led by Professor Michael Brown at the Royal Adelaide Hospital (RAH) with support from AusHealth Research, a division of AusHealth.
13 Oct, 2019
Telix Pharmaceuticals Limited (ASX:TLX, “Telix”, the “Company”) a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on “molecularly-targeted radiation” (MTR), today announced the completion of the integration of GE Healthcare’s cyclotron-based 68Ga (gallium) production data with Telix’s regulatory package for TLX591-CDx for the imaging of prostate cancer with Positron Emission Tomography (PET)1. In June of this year, GE Healthcare and Telix entered into a collaborative agreement in order to validate 68Ga produced on the PETtrace® cyclotron with Telix’s illumet™ prostate imaging product and to enable the data to be included in Telix’s product dossier.